InHeart, a pioneering medical device company, recently secured $11 million in fresh capital to accelerate the development and deployment of its innovative therapeutic and predictive cardiac solutions. The financing, led by Vesalius Biocapital IV and co-led by Elaia Partners, will enable InHeart to enhance its digital twin cardiac modeling technology and expand its commercial presence.

The company’s digital twin technology aims to create a precise, patient-specific virtual model of the heart, which will allow for highly accurate simulations and predictions of cardiac behavior. This technology not only aids in diagnosing cardiac conditions but also in planning and executing complex procedures with unprecedented precision.

Analyst Insights: Cardiac Ablation and the Promise of Digital Twin Technology in Cardiology

Cardiac ablation, a procedure used to correct heart rhythm problems, is one of the key applications of InHeart’s technology. By simulating different scenarios, physicians may be able to predict the outcomes of ablations with greater accuracy, thereby reducing the risk of complications and improving patient outcomes. This is particularly significant given the rising prevalence of atrial fibrillation (AFib) and other cardiac arrhythmias.

According to the medtech market intelligence team at LSI, the global cardiac ablation market is valued at approximately $5.9 billion and is expected to grow rapidly. In 2023 alone, 1.3 million cardiac ablations were performed worldwide, with a projected compound annual growth rate (CAGR) of 9.0% from 2023 to 2028. This growth is driven by the increasing prevalence of AFib and the growing demand for alternatives to pharmaceutical therapies.

Beyond cardiac ablation, the potential applications of InHeart’s digital twin technology are vast. LSI estimates that there are 17 million cardio procedures performed annually that could benefit from this advanced modeling technology. As the prevalence of cardiac conditions continues to rise, the demand for innovative, patient-specific solutions that improve procedural outcomes and patient safety is growing. The wide range of therapeutic and diagnostic applications of InHeart’s technology highlights the extensive impact solutions like this may have on the broader medtech market.

More on InHeart

InHeart has been one of the emerging medical device companies selected to present at previous LSI events, including LSI USA ‘24, LSI Europe ‘23, and LSI Europe ‘22. This year, LSI’s premier european medtech conference will be heading to Sintra, Portugal in September, and will convene hundreds of medtech companies like InHeart alongside top private equity and venture capital firms, global strategics, and more. 

A proprietary profile on InHeart is also available in LSI’s Companies & Deals database, providing coverage of over 6,000 medtech companies with associated deals, executive summaries, and more content from LSI events. Visit our website to learn more about our Companies & Deals database and full suite of medtech market research solutions.